









Markets
/
Stocks
/
nasdaq-tem
/

Tempus AI Inc

TEM

60.810USD

-2.700-4.25%

Market hours （ET）Quotes delayed by 15 min

10.81BMarket Cap

LossP/E TTM



Tempus AI Inc

60.810

-2.700-4.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tempus AI Inc

Currency: USD Updated: 2026-01-29

Key Insights

Tempus AI Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.42.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tempus AI Inc's Score

Industry at a Glance

Industry Ranking

72 / 393

Overall Ranking

176 / 4540

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Tempus AI Inc Highlights

StrengthsRisks

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 693.40M.

Undervalued

The company’s latest PE is -218.48, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 89.83M shares, decreasing 1.59% quarter-over-quarter.

Held by Ron Baron

Star Investor Ron Baron holds 263.25K shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

87.419

Target Price

+30.85%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Tempus AI Inc is 8.46, ranking 43 out of 393 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 334.21M, representing a year-over-year increase of 84.72%, while its net profit experienced a year-over-year increase of 5.46%.

Score

Industry at a Glance

Previous score

8.46

Change



Financials

6.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.66

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.52

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tempus AI Inc's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Tempus AI Inc is 7.30, ranking 141 out of 393 in the Biotechnology & Medical Research industry. Its current P/E ratio is -218.48, which is -122.05% below the recent high of 48.18 and -31.08% above the recent low of -286.38.

Score

Industry at a Glance

Previous score

7.30

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 72/393

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Tempus AI Inc is 7.60, ranking 276 out of 393 in the Biotechnology & Medical Research industry. The average price target is 90.00, with a high of 105.00 and a low of 80.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

87.419

Target Price

+30.85%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

541

Total

Median

Average

Company name

Ratings

Analysts

Tempus AI Inc

TEM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

108

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Tempus AI Inc is 6.90, ranking 165 out of 393 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 73.63 and the support level at 56.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.99

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.251

Sell

RSI(14)

42.722

Neutral

STOCH(KDJ)(9,3,3)

24.889

Sell

ATR(14)

4.179

High Vlolatility

CCI(14)

-178.239

Sell

Williams %R

88.353

Oversold

TRIX(12,20)

-0.049

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

65.568

Sell

MA10

66.755

Sell

MA20

66.665

Sell

MA50

68.710

Sell

MA100

76.935

Sell

MA200

69.630

Sell

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Tempus AI Inc is 5.00, ranking 141 out of 393 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 51.96%, representing a quarter-over-quarter increase of 18.62%. The largest institutional shareholder is The Vanguard, holding a total of 9.42M shares, representing 5.45% of shares outstanding, with 52.77% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Blue Media, LLC

18.14M

-29.78%

BK TL21 LLC

15.22M

Lefkofsky (Eric Paul)

11.70M

-0.14%

The Vanguard Group, Inc.

Star Investors

9.42M

+22.05%

Gray Media, LLC

9.27M

-1.42%

Baillie Gifford & Co.

Star Investors

9.69M

-19.86%

Red Sky LLC

8.06M

-15.13%

ARK Investment Management LLC

Star Investors

7.18M

-3.31%

SoftBank Group Corp

5.41M

BlackRock Institutional Trust Company, N.A.

5.38M

+72.19%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tempus AI Inc is 4.78, ranking 70 out of 393 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.